EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
BACKGROUND: 10-20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T��+�덽), in combination with perioperative CT for localized HER2+ GC. METHODS: This is a prospective, randomized, open-label,... Mehr ...
Dokumenttyp: | Artikel |
---|---|
Erscheinungsdatum: | 2019 |
Verlag/Hrsg.: |
BioMed Central
|
Schlagwörter: | Gastric cancer / Gastro-esophageal junction cancer / HER2 / Perioperative chemotherapy / Pertuzumab / Trastuzumab |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27465494 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173428 |